drugset / Trial / NCT02407912

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

NCT02407912

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the effect and toxicity of intrapleural administration of hypertonic cisplatin for malignant pleural effusion in patients with non-small-cell lung cancer.

Timeline

Start
2015-03
Primary completion
2018-03
Completion
2020-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Other

Indications